• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Chapter 12: systematic review of prognostic tests.第十二章:预后检测的系统评价。
J Gen Intern Med. 2012 Jun;27 Suppl 1(Suppl 1):S94-101. doi: 10.1007/s11606-011-1899-y.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.生物标志物对改良心脏风险指数在预测非心脏手术患者主要不良心脏事件和全因死亡率方面的比较和附加预后价值。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD013139. doi: 10.1002/14651858.CD013139.pub2.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
7
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.卫生技术评估中决策分析模型良好实践指南综述。
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.
10
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果:面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.

引用本文的文献

1
From Computation to Clinic.从计算到临床。
Biol Psychiatry Glob Open Sci. 2022 Apr 2;3(3):319-328. doi: 10.1016/j.bpsgos.2022.03.011. eCollection 2023 Jul.
2
The Prognostic Utility of Anticholinergic Burden Scales: An Integrative Review and Gap Analysis.抗胆碱能负担量表的预后效用:综合评价和差距分析。
Drugs Aging. 2023 Sep;40(9):763-783. doi: 10.1007/s40266-023-01050-4. Epub 2023 Jul 18.
3
Practical and validated tool to assess falls risk in the primary care setting: a systematic review.实用且经过验证的工具,用于评估初级保健环境中的跌倒风险:系统评价。
BMJ Open. 2021 Sep 29;11(9):e045431. doi: 10.1136/bmjopen-2020-045431.
4
Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome.肾小球滤过率估算方程对肾脏结局新型替代标志物的影响。
Kidney Res Clin Pract. 2021 Jun;40(2):220-230. doi: 10.23876/j.krcp.20.210. Epub 2021 Jun 9.
5
Subjective Motoric Complaints and New Onset Slow Gait.主观运动性抱怨和新发缓慢步态。
J Gerontol A Biol Sci Med Sci. 2021 Sep 13;76(10):e245-e252. doi: 10.1093/gerona/glaa321.
6
Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.用于局部皮肤黑色素瘤患者预后的基因表达谱检测的性能:系统评价和荟萃分析。
JAMA Dermatol. 2020 Sep 1;156(9):953-962. doi: 10.1001/jamadermatol.2020.1731.
7
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.皮肤黑色素瘤的预后基因表达谱分析:识别知识空白并评估临床获益。
JAMA Dermatol. 2020 Sep 1;156(9):1004-1011. doi: 10.1001/jamadermatol.2020.1729.
8
Computational approaches and machine learning for individual-level treatment predictions.个体治疗预测的计算方法和机器学习。
Psychopharmacology (Berl). 2021 May;238(5):1231-1239. doi: 10.1007/s00213-019-05282-4. Epub 2019 May 27.
9
Comparative Test Evaluation: Methods and Challenges.比较测试评估:方法与挑战。
J Gambl Stud. 2018 Dec;34(4):1109-1138. doi: 10.1007/s10899-018-9745-3.
10
What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences.我应该进行什么样的系统评价?医学和健康科学系统评价者的建议分类法和指南。
BMC Med Res Methodol. 2018 Jan 10;18(1):5. doi: 10.1186/s12874-017-0468-4.

本文引用的文献

1
Measuring the performance of markers for guiding treatment decisions.测量指导治疗决策标志物的性能。
Ann Intern Med. 2011 Feb 15;154(4):253-9. doi: 10.7326/0003-4819-154-4-201102150-00006.
2
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction.评估循环生物标志物、遗传生物标志物和成像生物标志物在心血管风险预测中的作用。
Circulation. 2011 Feb 8;123(5):551-65. doi: 10.1161/CIRCULATIONAHA.109.912568.
3
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.将净重新分类改进计算扩展到测量新生物标志物的有用性。
Stat Med. 2011 Jan 15;30(1):11-21. doi: 10.1002/sim.4085. Epub 2010 Nov 5.
4
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.心血管风险个体预测因素效应测量的进展:重新分类测量的作用。
Ann Intern Med. 2009 Jun 2;150(11):795-802. doi: 10.7326/0003-4819-150-11-200906020-00007.
5
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.心血管风险新标志物评估标准:美国心脏协会的科学声明
Circulation. 2009 May 5;119(17):2408-16. doi: 10.1161/CIRCULATIONAHA.109.192278. Epub 2009 Apr 13.
6
Genotype score in addition to common risk factors for prediction of type 2 diabetes.除常见风险因素外,基因型评分对2型糖尿病的预测作用
N Engl J Med. 2008 Nov 20;359(21):2208-19. doi: 10.1056/NEJMoa0804742.
7
Assessing the value of risk predictions by using risk stratification tables.使用风险分层表评估风险预测的价值。
Ann Intern Med. 2008 Nov 18;149(10):751-60. doi: 10.7326/0003-4819-149-10-200811180-00009.
8
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.用于分类或预测的生物标志物准确性的关键评估:研究设计标准
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8. doi: 10.1093/jnci/djn326. Epub 2008 Oct 7.
9
Measures to assess the prognostic ability of the stratified Cox proportional hazards model.评估分层Cox比例风险模型预后能力的措施。
Stat Med. 2009 Feb 1;28(3):389-411. doi: 10.1002/sim.3378.
10
Anemia and mortality in heart failure patients a systematic review and meta-analysis.心力衰竭患者的贫血与死亡率:一项系统评价和荟萃分析
J Am Coll Cardiol. 2008 Sep 2;52(10):818-27. doi: 10.1016/j.jacc.2008.04.061.

第十二章:预后检测的系统评价。

Chapter 12: systematic review of prognostic tests.

机构信息

Minneapolis Veterans Affairs Health Care System and School of Medicine, University of Minnesota, One Veterans Drive,Minneapolis, MN 55905, USA.

出版信息

J Gen Intern Med. 2012 Jun;27 Suppl 1(Suppl 1):S94-101. doi: 10.1007/s11606-011-1899-y.

DOI:10.1007/s11606-011-1899-y
PMID:22648680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3364355/
Abstract

A number of new biological markers are being studied as predictors of disease or adverse medical events among those who already have a disease. Systematic reviews of this growing literature can help determine whether the available evidence supports use of a new biomarker as a prognostic test that can more accurately place patients into different prognostic groups to improve treatment decisions and the accuracy of outcome predictions. Exemplary reviews of prognostic tests are not widely available, and the methods used to review diagnostic tests do not necessarily address the most important questions about prognostic tests that are used to predict the time-dependent likelihood of future patient outcomes. We provide suggestions for those interested in conducting systematic reviews of a prognostic test. The proposed use of the prognostic test should serve as the framework for a systematic review and to help define the key questions. The outcome probabilities or level of risk and other characteristics of prognostic groups are the most salient statistics for review and perhaps meta-analysis. Reclassification tables can help determine how a prognostic test affects the classification of patients into different prognostic groups, hence their treatment. Review of studies of the association between a potential prognostic test and patient outcomes would have little impact other than to determine whether further development as a prognostic test might be warranted.

摘要

目前有许多新的生物标志物被研究作为已经患有疾病的人预测疾病或不良医疗事件的指标。对这一不断增长的文献的系统评价可以帮助确定现有证据是否支持将新的生物标志物用作预后试验,以更准确地将患者分为不同的预后组,从而改善治疗决策和结果预测的准确性。预后试验的范例性综述并不广泛,并且用于审查诊断测试的方法不一定解决用于预测未来患者结果的时间依赖性可能性的预后测试的最重要问题。我们为有兴趣对预后测试进行系统评价的人提供了建议。拟议的预后测试的使用应作为系统评价的框架,并有助于定义关键问题。预后组的预后概率或风险水平和其他特征是最突出的统计数据,可供审查和可能进行荟萃分析。重新分类表有助于确定预后测试如何影响患者进入不同预后组的分类,从而影响其治疗。除了确定是否有必要进一步开发为预后测试外,对潜在预后测试与患者结局之间的关联的研究进行审查的影响将很小。